Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma

Pediatric Blood and Cancer

Volumn 58, Issue 4, 2012, Pages 539-544

  Schmid, Irene ^a   Häberle, Beate ^a   Albert, Michael H ^a   Corbacioglu, Selim ^b   Fröhlich, Birgit ^c   Graf, Norbert ^d   Kammer, Birgit ^a   Kontny, Udo ^e   Leuschner, Ivo ^f   Scheel Walter, Hans Gerhard ^g   Scheurlen, Wolfram ^h   Werner, Sebastian ⁱ   Wiesel, Thomas ^j   von Schweinitz, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h University Witten Herdecke ^*  (Germany)

ⁱ JUSTUS LIEBIG UNIVERSITY   (Germany)

^j UNIVERSITY OF WITTEN HERDECKE   (Germany)

more..

Author keywords

Cisplatin; Doxorubicin; Hepatocellular carcinoma; Pediatric; PLADO; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN; SORAFENIB;

ADOLESCENT; ARTICLE; ASPERGILLOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHILD; CISPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856852669     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23295     Document Type: Article

References (24)

1. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20: 2798-2804.
2. Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008; 13: 812-820.
3. Chen JC, Chen CC, Chen WJ, et al. Hepatocellular carcinoma in children: Clinical review and comparison with adult cases. J Pediatr Surg 1998; 33: 1350-1354.
4. Czauderna P. Adult type vs. Childhood hepatocellular carcinoma-Are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 2002; 39: 519-523.
5. Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: Common and distinctive aspects. Med Pediatr Oncol 2002; 39: 530-535.
6. Schmid I, Albert MH, Häberle B, et al. HB99-Hepatozelluläre Karzinome: Behandlungsergebnisse und neue Konzepte. Monatsschr Kinderheilkd 2008; 156: 412.
7. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular carcinoma in children and adolescents: Results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002; 20: 2789-2797.
8. Czauderna P, Maibach R, Aronson D, et al. Hepatocellular carcinoma in children: Results of the second prospective study of the International Society of Pediatric Oncology (SIOP): SIOPEL 2. Med Pediatr Oncol 2003; 41: 269.
9. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
10. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
11. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858.
12. Carter CA, Chen C, Brink C, et al. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007; 59: 183-195.
13. Vincent P, Zhang X, Chen C, et al. Chemotherapy with the raf kinase inhibitor BAY43-9006 in combination with irinotecane, vinorelbine, or gemcitabine is well tolerated and efficacious in preclinical xenograft models. Proc Am Soc Clin Oncol 2002; 21: a1900.
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
15. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22: 391-398.
16. Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma. Gastrointestinal Cancers Symposium, Orlando, FL: American Society of Clinical Oncology; 2008:a128.
17. Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Cancer Chemother Pharmacol 2008; 61: 535-548.
18. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial. Eur J Cancer 2009; 45: 579-587.
19. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005; 23: 1245-1252.
20. National Cancer Institute. CTC v3.0 and Common Terminology Criteria for Adverse Events v4.o (CTCAE). NCI; 2010.
21. Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009; 14: 291-302.
22. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118.
23. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol 2011 Apr 28 [Epub ahead of print].
24. Widemann BC, Fox PC, Adamson PC, et al. Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. J Clin Oncol 2009; 27: 10012.